Two critical components of the HR system are encoded by BRCA1 and BRCA2. Loss of the wild-type allele of either of these two genes is frequently observed in familial breast and ovarian cancers [19] and BRCA1/2-deficient ovarian cancer patients have generally better responses to platinum and are associated with better clinical outcome [20]. This evidence concerns the gene BRCA2 and ovarian carcinoma.